The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) significantly improve the outcomes as an initial treatment in non-small cell lung cancer (NSCLC) patients with activating EGFR mutations compared with standard platinum-doublet chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.